ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet13144ometendo-13144Research ArticleОБЗОРЫREVIEWSЭволюция планирования беременности при гиперпролактинемииEvolution of pregnancy planning in hyperprolactinemiahttps://orcid.org/0000-0002-0327-4619ДзерановаЛ. К.DzeranovaL. K.

Дзеранова Лариса Константиновна, д.м.н. 

Москва

Larisa K. Dzeranova, MD, PhD

Moscow

dzeranovalk@yandex.ruhttps://orcid.org/0000-0001-7470-1676ВоротниковаС. Ю.VorotnikovaS. Yu.

Воротникова Светлана Юрьевна, к.м.н. 

Москва

Svetlana Y. Vorotnikova, MD, PhD

Moscow

bra_svetix@list.ruhttps://orcid.org/0000-0001-6539-466XПигароваЕ. А.PigarovaE. A.

Пигарова Екатерина Александровна, д.м.н. 

Москва

kpigarova@gmail.comНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation202417062024212188194Copyright © Дзеранова Л.К., Воротникова С.Ю., Пигарова Е.А., 20242024Дзеранова Л.К., Воротникова С.Ю., Пигарова Е.А.Dzeranova L.K., Vorotnikova S.Y., Pigarova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/13144

Гиперпролактинемия имеет множественную этиологию и является наиболее частым эндокринным проявлением патологии гипоталамо-гипофизарной оси. Гиперпролактинемический гипогонадизм представляет большой научный ввиду распространенности эндокринной патологии в репродуктивном периоде и влияния на метаболические процессы. Гиперпролактинемия – одно из серьезных препятствий на пути к реализации детородной функции как у женщин, так и мужчин. В статье рассмотрены актуальные вопросы диагностики и тактики ведения пациенток с гиперпролактинемией различной этиологии в рамках преконцепционной подготовки.

Hyperprolactinemia has multiple etiologies and is the most common endocrine manifestation of pathology of the hypo­thalamic-pituitary axis. Hyperprolactinemic hypogonadism is of great scientific interest due to the prevalence of endocrine pathology in the reproductive period and its effect on metabolic processes. Hyperprolactinemia is one of the serious obstacles to the implementation of reproductive function in both women and men. The article discusses current issues of diagnosis and management tactics for patients with hyperprolactinemia of various etiologies within the framework of preconception preparation.

гиперпролактинемияпролактинаденома гипофизабеременностьгестацияагонисты дофаминакаберголинhyperprolactinemiaprolactinpituitary adenomapregnancygestationdopamine agonistscabergolineReferencesGrattan DR, Jasoni CL, Liu X. et al. Prolactin regulation of gonadotropin-releasing hormone neurons to suppress luteinizing hormone secretion in mice. Endocrinology. 2007;148(9):4344-51. doi: https://doi.org/10.1210/en.2007-0403Grattan DR, Jasoni CL, Liu X. et al. Prolactin regulation of gonadotropin-releasing hormone neurons to suppress luteinizing hormone secretion in mice. Endocrinology. 2007;148(9):4344-51. doi: https://doi.org/10.1210/en.2007-0403Brown RS, Piet R, Herbison AE. et al. Differential actions of prolactin on electrical activity and intracellular signal transduction in hypothalamic neurons. Endocrinology. 2012;153(5):2375-84. doi: https://doi.org/10.1210/en.2011-2005Brown RS, Piet R, Herbison AE. et al. Differential actions of prolactin on electrical activity and intracellular signal transduction in hypothalamic neurons. Endocrinology. 2012;153(5):2375-84. doi: https://doi.org/10.1210/en.2011-2005Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. Endocrinology. 2011;152(2):526-35. doi: https://doi.org/10.1210/en.2010-0668Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. Endocrinology. 2011;152(2):526-35. doi: https://doi.org/10.1210/en.2010-0668Sonigo C, Bouilly J, Carré N. et al. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest. 2012;122(10):3791-5. doi: https://doi.org/10.1172/JCI63937Sonigo C, Bouilly J, Carré N. et al. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest. 2012;122(10):3791-5. doi: https://doi.org/10.1172/JCI63937Millar RP, Sonigo C, Anderson RA. et al. Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. J Endocr Soc. 2017;1(11):1362-1371. doi: https://doi.org/10.1210/js.2017-00328Millar RP, Sonigo C, Anderson RA. et al. Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. J Endocr Soc. 2017;1(11):1362-1371. doi: https://doi.org/10.1210/js.2017-00328Donato J Jr, Frazão R. Interactions between prolactin and kisspeptin to control reproduction. Arch Endocrinol Metab. 2016;60(6):587-595. doi: https://doi.org/10.1590/2359-3997000000230Donato J Jr, Frazão R. Interactions between prolactin and kisspeptin to control reproduction. Arch Endocrinol Metab. 2016;60(6):587-595. doi: https://doi.org/10.1590/2359-3997000000230Vlahos NP, Bugg EM, Shamblott MJ. et al. Prolactin receptor gene expression and immunolocalization of the prolactin receptor in human luteinized granulosa cells. Mol Hum Reprod. 2001;7(11):1033-8. doi: https://doi.org/10.1093/molehr/7.11.1033Vlahos NP, Bugg EM, Shamblott MJ. et al. Prolactin receptor gene expression and immunolocalization of the prolactin receptor in human luteinized granulosa cells. Mol Hum Reprod. 2001;7(11):1033-8. doi: https://doi.org/10.1093/molehr/7.11.1033Репродуктивная эндокринология Йена и Джаффе. Физиология, патофизиология, клиника, диагностика и лечение / Джером Ф. Штраус III, Роберт Л. Барбьери, Антонио Р. Гарджуло. — 8-е изд. — Москва : ООО «Издательство «Медицинское информационное агентство», 2022. — 1200 + XVI с. : ил.Репродуктивная эндокринология Йена и Джаффе. Физиология, патофизиология, клиника, диагностика и лечение / Джером Ф. Штраус III, Роберт Л. Барбьери, Антонио Р. Гарджуло. — 8-е изд. — Москва : ООО «Издательство «Медицинское информационное агентство», 2022. — 1200 + XVI с. : ил.Андреева Е.Н. Гиперпролактинемия у женщин репродуктивного возраста: что должен помнить врач / Е.Н. Андреева, Е.В. Шереметьева, О.Р. Григорян // Акушерство и гинекология. — 2021. — Т. 9. — С. 204-210Андреева Е.Н. Гиперпролактинемия у женщин репродуктивного возраста: что должен помнить врач / Е.Н. Андреева, Е.В. Шереметьева, О.Р. Григорян // Акушерство и гинекология. — 2021. — Т. 9. — С. 204-210Castilla A, García C, Cruz-Soto M. et al. Prolactin in ovarian follicular fluid stimulates endothelial cell proliferation. J Vasc Res. 2010;47(1):45-53. doi: https://doi.org/10.1159/000231720Castilla A, García C, Cruz-Soto M. et al. Prolactin in ovarian follicular fluid stimulates endothelial cell proliferation. J Vasc Res. 2010;47(1):45-53. doi: https://doi.org/10.1159/000231720Auriemma RS, Del Vecchio G, Scairati R. et al. The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology. Front Endocrinol (Lausanne). 2020;11:594370. doi: https://doi.org/10.3389/fendo.2020.594370Auriemma RS, Del Vecchio G, Scairati R. et al. The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology. Front Endocrinol (Lausanne). 2020;11:594370. doi: https://doi.org/10.3389/fendo.2020.594370Levina VV, Nolen B, Su Y. et al. Biological significance of prolactin in gynecologic cancers. Cancer Res. 2009;69(12):5226-33. doi: https://doi.org/10.1158/0008-5472.CAN-08-4652Levina VV, Nolen B, Su Y. et al. Biological significance of prolactin in gynecologic cancers. Cancer Res. 2009;69(12):5226-33. doi: https://doi.org/10.1158/0008-5472.CAN-08-4652Alvarez-Payares JC, Bello-Simanca JD, De La Peña-Arrieta EJ. et al. Common Pitfalls in the Interpretation of Endocrine Tests. Front Endocrinol (Lausanne). 2021;12:727628. doi: https://doi.org/10.3389/fendo.2021.727628Alvarez-Payares JC, Bello-Simanca JD, De La Peña-Arrieta EJ. et al. Common Pitfalls in the Interpretation of Endocrine Tests. Front Endocrinol (Lausanne). 2021;12:727628. doi: https://doi.org/10.3389/fendo.2021.727628Koniares K, Benadiva C, Engmann L. et al. Macroprolactinemia: a mini-review and update on clinical practice. F S Rep. 2023;4(3):245-250. doi: https://doi.org/10.1016/j.xfre.2023.05.005Koniares K, Benadiva C, Engmann L. et al. Macroprolactinemia: a mini-review and update on clinical practice. F S Rep. 2023;4(3):245-250. doi: https://doi.org/10.1016/j.xfre.2023.05.005Shimatsu A, Hattori N. Macroprolactinemia: Diagnostic, clinical, and pathogenic significance. Clin Dev Immunol. 2012;2012:167132. doi: https://doi.org/10.1155/2012/167132Shimatsu A, Hattori N. Macroprolactinemia: Diagnostic, clinical, and pathogenic significance. Clin Dev Immunol. 2012;2012:167132. doi: https://doi.org/10.1155/2012/167132Thirunavakkarasu K, Dutta P, Sridhar S. et al. Macroprolactinemia in hyperprolactinemic infertile women. Endocrine. 2013;4:750–5. doi: https://doi.org/10.1007/s12020-013-9925-yThirunavakkarasu K, Dutta P, Sridhar S. et al. Macroprolactinemia in hyperprolactinemic infertile women. Endocrine. 2013;4:750–5. doi: https://doi.org/10.1007/s12020-013-9925-yVilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of macroprolactinemia. Arq Bras Endocrinol Metabol. 2014;58:9–22. doi: https://doi.org/10.1590/0004-2730000003002Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of macroprolactinemia. Arq Bras Endocrinol Metabol. 2014;58:9–22. doi: https://doi.org/10.1590/0004-2730000003002Yang W, Guo Z, Zhou Y. et al. Optimization of a screening method for macroprolactinemia. J Chromatogr B. 2021;1175:122723. doi: https://doi.org/10.1016/j.jchromb.2021.122723Yang W, Guo Z, Zhou Y. et al. Optimization of a screening method for macroprolactinemia. J Chromatogr B. 2021;1175:122723. doi: https://doi.org/10.1016/j.jchromb.2021.122723Thirunavakkarasu K, Dutta P, Sridhar S. et al. Macroprolactinemia in hyperprolactinemic infertile women. Endocrine. 2013;4:750–5. doi: https://doi.org/10.1007/s12020-013-9925-yThirunavakkarasu K, Dutta P, Sridhar S. et al. Macroprolactinemia in hyperprolactinemic infertile women. Endocrine. 2013;4:750–5. doi: https://doi.org/10.1007/s12020-013-9925-yHayashida SAY, Marcondes JAM, Soares JM. et al. Evaluation of macroprolactinemia in 259 women under investigation for polycystic ovary syndrome. Clin Endocrinol 2014;80:616–8. doi: https://doi.org/10.1111/cen.12266Hayashida SAY, Marcondes JAM, Soares JM. et al. Evaluation of macroprolactinemia in 259 women under investigation for polycystic ovary syndrome. Clin Endocrinol 2014;80:616–8. doi: https://doi.org/10.1111/cen.12266Kalsi AK, Halder A, Jain M. et al. Prevalence and reproductive manifestations of macroprolactinemia. Endocrine. 2019;63(2):332-340. doi: https://doi.org/10.1007/s12020-018-1770-6Kalsi AK, Halder A, Jain M. et al. Prevalence and reproductive manifestations of macroprolactinemia. Endocrine. 2019;63(2):332-340. doi: https://doi.org/10.1007/s12020-018-1770-6Hu Y, Ni J, Zhang B, Cheng W, Zhang H, Ye H, Ji L, Lu B, Guan M. Establishment of reference intervals of monomeric prolactin to identify macroprolactinemia in Chinese patients with increased total prolactin. BMC Endocr Disord. 2021 Oct 7;21(1):197. doi: https://10.1186/s12902-021-00861-z.Hu Y, Ni J, Zhang B, Cheng W, Zhang H, Ye H, Ji L, Lu B, Guan M. Establishment of reference intervals of monomeric prolactin to identify macroprolactinemia in Chinese patients with increased total prolactin. BMC Endocr Disord. 2021 Oct 7;21(1):197. doi: https://10.1186/s12902-021-00861-z.Hattori N, Ishihara T, Saiki Y, Shimatsu A. Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long-term follow-up. Clin Endocrinol. 2010;73:792–7. doi: https://doi.org/10.1111/j.1365-2265.2010.03880.xHattori N, Ishihara T, Saiki Y, Shimatsu A. Macroprolactinaemia in patients with hyperprolactinaemia: composition of macroprolactin and stability during long-term follow-up. Clin Endocrinol. 2010;73:792–7. doi: https://doi.org/10.1111/j.1365-2265.2010.03880.xWallace IR, Satti N, Courtney CH. et al. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J Clin Endocrinol Metab. 2010;95: 3268–71. doi: https://doi.org/10.1210/jc.2010-0114Wallace IR, Satti N, Courtney CH. et al. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J Clin Endocrinol Metab. 2010;95: 3268–71. doi: https://doi.org/10.1210/jc.2010-0114Nishiyama N, Hattori N, Aisaka K. et al. Macroprolactin in mothers and their babies: what is its origin? Clin Chem Lab Med. 2024. doi: https://doi.org/10.1515/cclm-2024-0235Nishiyama N, Hattori N, Aisaka K. et al. Macroprolactin in mothers and their babies: what is its origin? Clin Chem Lab Med. 2024. doi: https://doi.org/10.1515/cclm-2024-0235Petersenn S, Fleseriu M, Casanueva FF. et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722-740. doi: https://doi.org/10.1038/s41574-023-00886-5Petersenn S, Fleseriu M, Casanueva FF. et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722-740. doi: https://doi.org/10.1038/s41574-023-00886-5Melmed S, Casanueva FF, Hoffman AR. et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88. doi: https://doi.org/10.1210/jc.2010-1692Melmed S, Casanueva FF, Hoffman AR. et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88. doi: https://doi.org/10.1210/jc.2010-1692Coopmans EC, Korbonits M. Molecular genetic testing in the management of pituitary disease. Clin Endocrinol (Oxf). 2022;97(4):424-435. doi: https://doi.org/10.1111/cen.14706Coopmans EC, Korbonits M. Molecular genetic testing in the management of pituitary disease. Clin Endocrinol (Oxf). 2022;97(4):424-435. doi: https://doi.org/10.1111/cen.14706Тарасова Т.С., Пигарова Е.А., Дзеранова Л.К., Тюльпаков А.Н., Дедов И.И. Выявление метаболических изменений у пациентов с семейными аденомами гипофиза, ассоциированными с мутациями в гене AIP // Ожирение и метаболизм. — 2017. — Т. 14. — №1. — С. 48-51. doi: https://doi.org/10.14341/omet2017148-51.Tarasova TS, Pigarova EA, Dzeranova LK, Tiulpakov AN, Dedov II. Metabolic changes in patients with familial pituitary adenomas associated with mutations in the AIP gene. Obesity and metabolism. 2017;14(1):48-51. (In Russ.). doi: https://doi.org/10.14341/omet2017148-51.de Laat JM, Dekkers OM, Pieterman CR, et al. Long‐term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 study group (DMSG). J Clin Endocrinol Metab. 2015;100:3288‐3296. doi: https://doi.org/10.1210/JC.2015-2015de Laat JM, Dekkers OM, Pieterman CR, et al. Long‐term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 study group (DMSG). J Clin Endocrinol Metab. 2015;100:3288‐3296. doi: https://doi.org/10.1210/JC.2015-2015Chahal HS, Chapple JP, Frohman LA. et al. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21(7):419-27. doi: https://doi.org/10.1016/j.tem.2010.02.007Chahal HS, Chapple JP, Frohman LA. et al. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21(7):419-27. doi: https://doi.org/10.1016/j.tem.2010.02.007Lima AD, Alves VR, Rocha AR, Martinhago AC, et al. Preimplantation genetic diagnosis for a patient with multiple endocrine neoplasia type 1: case report. JBRA Assist Reprod. 2018;22(1):67-70. doi: https://doi.org/10.5935/1518-0557.20180010Lima AD, Alves VR, Rocha AR, Martinhago AC, et al. Preimplantation genetic diagnosis for a patient with multiple endocrine neoplasia type 1: case report. JBRA Assist Reprod. 2018;22(1):67-70. doi: https://doi.org/10.5935/1518-0557.20180010Buskila D, Berezin M, Gur H. et al. Autoantibody profile in the sera of women with hyperprolactinemia. J Autoimmun. 1995;8(3):415-24. doi: https://doi.org/10.1006/jaut.1995.0033Buskila D, Berezin M, Gur H. et al. Autoantibody profile in the sera of women with hyperprolactinemia. J Autoimmun. 1995;8(3):415-24. doi: https://doi.org/10.1006/jaut.1995.0033Кривонос М.И., Зайнулина М.С., Сельков С.А. Антифосфолипидный синдром и ранние репродуктивные потери // Акушерство, гинекология и репродукция. — 2016. — Т. 10. — №4. — С. 114-122Кривонос М.И., Зайнулина М.С., Сельков С.А. Антифосфолипидный синдром и ранние репродуктивные потери // Акушерство, гинекология и репродукция. — 2016. — Т. 10. — №4. — С. 114-122Praprotnik S, Agmon-Levin N, Porat-Katz BS, et al. Prolactin’s role in the pathogenesis of the antiphospholipid syndrome. Lupus. 2010;19(13):1515-9. doi: https://doi.org/10.1177/0961203310373781Praprotnik S, Agmon-Levin N, Porat-Katz BS, et al. Prolactin’s role in the pathogenesis of the antiphospholipid syndrome. Lupus. 2010;19(13):1515-9. doi: https://doi.org/10.1177/0961203310373781Wallaschofski H, Lohmann T, Hild E, et al. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost. 2006;96(1):38-44. doi: https://doi.org/10.1160/TH05-09-0634Wallaschofski H, Lohmann T, Hild E, et al. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost. 2006;96(1):38-44. doi: https://doi.org/10.1160/TH05-09-0634Sherer Y, Blank M, Shoenfeld Y. Immunomodulation of experimental antiphospholipid syndrome. Scand J Rheumatol Suppl. 1998;107:48-52. doi: https://doi.org/10.1080/03009742.1998.11720761Sherer Y, Blank M, Shoenfeld Y. Immunomodulation of experimental antiphospholipid syndrome. Scand J Rheumatol Suppl. 1998;107:48-52. doi: https://doi.org/10.1080/03009742.1998.11720761Raverot V, Perrin P, Chanson P, et al. Prolactin immunoassay: does the high-dose hook effect still exist? Pituitary. 2022;25(4):653-657. doi: https://doi.org/10.1007/s11102-022-01246-8Raverot V, Perrin P, Chanson P, et al. Prolactin immunoassay: does the high-dose hook effect still exist? Pituitary. 2022;25(4):653-657. doi: https://doi.org/10.1007/s11102-022-01246-8Saei Ghare Naz M, Rostami Dovom M, Ramezani Tehrani F. The Menstrual Disturbances in Endocrine Disorders: A Narrative Review. Int J Endocrinol Metab. 2020;18(4):e106694. doi: https://doi.org/10.5812/ijem.106694/Saei Ghare Naz M, Rostami Dovom M, Ramezani Tehrani F. The Menstrual Disturbances in Endocrine Disorders: A Narrative Review. Int J Endocrinol Metab. 2020;18(4):e106694. doi: https://doi.org/10.5812/ijem.106694/Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205-13. doi: https://doi.org/10.1530/EJE-14-0848Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205-13. doi: https://doi.org/10.1530/EJE-14-0848Прегравидарная подготовка. Клинический протокол Междисциплинарной ассоциации специалистов репродуктивной медицины (МАРС). Версия 3.1 / [Коллектив авторов]. —М.: Редакция журнала StatusPraesens, 2024. — 124 с.Прегравидарная подготовка. Клинический протокол Междисциплинарной ассоциации специалистов репродуктивной медицины (МАРС). Версия 3.1 / [Коллектив авторов]. —М.: Редакция журнала StatusPraesens, 2024. — 124 с.Luger A, Broersen LHA, Biermasz NR, et al. ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol. 2021;185(3):G1-G33. doi: https://doi.org/10.1530/EJE-21-0462Luger A, Broersen LHA, Biermasz NR, et al. ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol. 2021;185(3):G1-G33. doi: https://doi.org/10.1530/EJE-21-0462Giraldi EA, Ioachimescu AG. The Role of Dopamine Agonists in Pituitary Adenomas. Endocrinol Metab Clin North Am. 2020;49(3):453-474. doi: https://doi.org/10.1016/j.ecl.2020.05.006Giraldi EA, Ioachimescu AG. The Role of Dopamine Agonists in Pituitary Adenomas. Endocrinol Metab Clin North Am. 2020;49(3):453-474. doi: https://doi.org/10.1016/j.ecl.2020.05.006Huang HY, Lin SJ, Zhao WG, Wu ZB. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review. Metab Brain Dis. 2018;33(3):969-976. doi: https://doi.org/10.1007/s11011-018-0217-3Huang HY, Lin SJ, Zhao WG, Wu ZB. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review. Metab Brain Dis. 2018;33(3):969-976. doi: https://doi.org/10.1007/s11011-018-0217-3Huang W, Molitch ME. Pituitary Tumors in Pregnancy. Endocrinol Metab Clin North Am. 2019;48(3):569-581. doi: https://doi.org/10.1016/j.ecl.2019.05.004Huang W, Molitch ME. Pituitary Tumors in Pregnancy. Endocrinol Metab Clin North Am. 2019;48(3):569-581. doi: https://doi.org/10.1016/j.ecl.2019.05.004Hurault-Delarue C, Montastruc JL, Beau AB. et al. Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet. 2014;290:263–70Hurault-Delarue C, Montastruc JL, Beau AB. et al. Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet. 2014;290:263–70Sant’ Anna BG, Musolino NRC, Gadelha MR. et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary. 2020;23(2):120-128. doi: https://doi.org/10.1007/s11102-019-01008-zSant’ Anna BG, Musolino NRC, Gadelha MR. et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary. 2020;23(2):120-128. doi: https://doi.org/10.1007/s11102-019-01008-zGlezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary. 2020;23(1):65-69. doi: https://doi.org/10.1007/s11102-019-01010-5Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary. 2020;23(1):65-69. doi: https://doi.org/10.1007/s11102-019-01010-5Huang W, Molitch ME. Pituitary Tumors in Pregnancy. Endocrinol Metab Clin North Am. 2019;48(3):569-581. doi: https://doi.org/10.1016/j.ecl.2019.05.004Huang W, Molitch ME. Pituitary Tumors in Pregnancy. Endocrinol Metab Clin North Am. 2019;48(3):569-581. doi: https://doi.org/10.1016/j.ecl.2019.05.004Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, et al. Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(3):e32–41. doi: https://doi.org/10.1210/clinem/dgz144Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, et al. Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(3):e32–41. doi: https://doi.org/10.1210/clinem/dgz144Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol. 2012;166(5):779-86. doi: https://doi.org/10.1530/EJE-11-1000Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol. 2012;166(5):779-86. doi: https://doi.org/10.1530/EJE-11-1000Buchfelder M, Zhao Y, Schlaffer SM. Surgery for Prolactinomas to Date. Neuroendocrinology. 2019;109(1):77-81. doi: https://doi.org/10.1159/000497331Buchfelder M, Zhao Y, Schlaffer SM. Surgery for Prolactinomas to Date. Neuroendocrinology. 2019;109(1):77-81. doi: https://doi.org/10.1159/000497331Magro E, Graillon T, Lassave J. et el. Complications Related to the Endoscopic Endonasal Transsphenoidal Approach for Nonfunctioning Pituitary Macroadenomas in 300 Consecutive Patients. World Neurosurg. 2016;89:442-53. doi: https://doi.org/10.1016/j.wneu.2016.02.059Magro E, Graillon T, Lassave J. et el. Complications Related to the Endoscopic Endonasal Transsphenoidal Approach for Nonfunctioning Pituitary Macroadenomas in 300 Consecutive Patients. World Neurosurg. 2016;89:442-53. doi: https://doi.org/10.1016/j.wneu.2016.02.059Kamel A, Halim AA, Shehata M. et al. Changes in serum prolactin level during intracytoplasmic sperm injection, and efect on clinical pregnancy rate: a prospective observational study. BMC Pregnancy Childbirth. 2018;18:141. doi: https://doi.org/10.1186/s12884-018-1783-4Kamel A, Halim AA, Shehata M. et al. Changes in serum prolactin level during intracytoplasmic sperm injection, and efect on clinical pregnancy rate: a prospective observational study. BMC Pregnancy Childbirth. 2018;18:141. doi: https://doi.org/10.1186/s12884-018-1783-4Herman T, Csehely S, Orosz M, et al. Impact of Endocrine Disorders on IVF Outcomes: Results from a Large, Single-Centre, Prospective Study. Reprod Sci. 2023;30(6):1878-1890. doi: https://doi.org/10.1007/s43032-022-01137-0Herman T, Csehely S, Orosz M, et al. Impact of Endocrine Disorders on IVF Outcomes: Results from a Large, Single-Centre, Prospective Study. Reprod Sci. 2023;30(6):1878-1890. doi: https://doi.org/10.1007/s43032-022-01137-0Duan Y, Liu X, Hou W, et al. No impact of treated hyperprolactinemia on cumulative live birth rate and perinatal outcomes in in vitro fertilization-embryo transfer. J Obstet Gynaecol Res. 2019;45:1236–1244Duan Y, Liu X, Hou W, et al. No impact of treated hyperprolactinemia on cumulative live birth rate and perinatal outcomes in in vitro fertilization-embryo transfer. J Obstet Gynaecol Res. 2019;45:1236–1244

The authors declare that there are no conflicts of interest present.